NCT06224452View on ClinicalTrials.gov

Is Ibrutinib-related Atrial Fibrillation Dose Dependent

Not yet recruitingOBSERVATIONAL
Enrollment

18,000

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

May 1, 2024

Study Completion Date

July 1, 2024

Conditions
Hematological MalignancyAtrial Fibrillation
Interventions
DRUG

ibrutinib exposure

We will extract all atrial fibrillation cases involving adult patients associated with ibrutinib exposure with an available ibrutinib daily dose

Trial Locations (1)

Unknown

Caen University Hospital, Department of Pharmacology, Caen

All Listed Sponsors
lead

University Hospital, Caen

OTHER

NCT06224452 - Is Ibrutinib-related Atrial Fibrillation Dose Dependent | Biotech Hunter | Biotech Hunter